Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte’s human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement.
“At Vaxcyte, we are proud to cultivate a culture that values collaboration, innovation and a shared commitment to our mission,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We have built an extraordinary team, and we recognize that our success is intricately tied to the strength and well-being of our people. Whitney’s role as our Chief People Officer will be instrumental in championing our people-first approach and ensuring that our workforce continues to grow and thrive.”
“We’re thrilled to welcome Whitney to Vaxcyte as our first Chief People Officer,” said Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte. “She’s an accomplished leader with an impressive background of successfully leading people strategies for fast-growth and established companies across a breadth of industries. Whitney will play an important role in maintaining our strong company culture and supporting our organizational growth strategies as we scale the Company to advance our pipeline of novel vaccine candidates, including our lead pneumococcal conjugate vaccine franchise programs, VAX-24 and VAX-31.”
“I’m delighted to join Vaxcyte, a mission-driven company working to address serious bacterial infections to protect every child born and every adult at risk across the globe,” said Ms. Jones. “It’s a time of incredible growth for the Company and I’m honored to work alongside such a talented team as we work to realize Vaxcyte’s long-term vision. I look forward to fostering the well-established dynamic and vibrant culture as we continue to scale and prepare for the anticipated global commercialization of potentially life-saving vaccines.”
SOURCE: GlobeNewswire